Get started
Author

Viktor P. Volok

Observed names: V. P. Volok, V.P. Volok, Viktor P Volok, Viktor Volok, Volok, Viktor, Volok, Viktor P., Волок Виктор Петрович
Institution: InSysBio (Russia)
Observed institutions: Peoples' Friendship University of Russia, Russian Academy of Sciences, Lomonosov Moscow State University, InSysBio (Russia), Institute of Bioorganic Chemistry, Chumakov Institute of Poliomyelitis and Viral Encephalitides
ORCID: 0000-0002-9659-723X
Observed ORCID: 0000-0002-9659-723X
OpenAlex ID: A5048022891
Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies
2021 · Liubov I. Kozlovskaya, Anastasia N. Piniaeva, et al. · Emerging Microbes & Infections · 76
Ixodid ticks and tick-borne encephalitis virus prevalence in the South Asian part of Russia (Republic of Tuva)
2019 · Ivan Kholodilov, Oxana Belova, et al. · Ticks and Tick-borne Diseases · 37
Structural characterization of β‐propiolactone inactivated severe acute respiratory syndrome coronavirus 2 ( SARS‐CoV ‐2) particles
2021 · Dmitry V. Bagrov, Grigory S. Glukhov, et al. · Microscopy Research and Technique · 27
PDF
Experimental Assessment of Possible Factors Associated with Tick-Borne Encephalitis Vaccine Failure
2021 · Ksenia Tuchynskaya, Viktor Volok, et al. · Microorganisms · 27
PDF
Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses
2021 · Liubov I. Kozlovskaya, Viktor P. Volok, et al. · European Journal of Medicinal Chemistry · 21
Evervac: phase I/II study of immunogenicity and safety of a new adjuvant-free TBE vaccine cultivated in Vero cell culture
2020 · Mikhail F. Vorovitch, Karina G. Grishina, et al. · Human Vaccines & Immunotherapeutics · 17
SARS-CoV-2 infection in children in Moscow in 2020: clinical features and impact on circulation of other respiratory viruses
2022 · Alexander S. Yakovlev, Ilmira K. Belyaletdinova, et al. · International Journal of Infectious Diseases · 16
PDF
Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18–60 and 60+ Age Cohorts
2023 · Ilya V. Gordeychuk, Liubov I. Kozlovskaya, et al. · Viruses · 14
PDF
Progressive Course of Chronic Tick-Borne Encephalitis Manifesting as Amyotrophic Lateral Sclerosis-like Syndrome 35 Years after the Acute Disease
2022 · Viktor P. Volok, Larissa V. Gmyl, et al. · Brain Sciences · 12
PDF
Safety and immunogenicity of inactivated whole virion vaccine CoviVac against COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase I/II clinical trial
2022 · Aydar A Ishmukhametov, Aleksandra A Siniugina, et al. · medRxiv · 8
PDF
Cationic Perylene Antivirals with Aqueous Solubility for Studies In Vivo
2022 · Anna A. Shtro, Anzhelika V. Garshinina, et al. · Pharmaceuticals · 6
PDF
Phenotypic assessment of antiviral activity for spiro‐annulated oxepanes and azepenes
2024 · Dmitry I. Osolodkin, Liubov I. Kozlovskaya, et al. · Chemical Biology & Drug Design · 5
Effect of immature tick-borne encephalitis virus particles on antiviral activity of 5-aminoisoxazole-3-carboxylic acid adamantylmethyl esters
2021 · Ksenia K. Tuchynskaya, Anastasiia D. Fomina, et al. · Journal of General Virology · 5
Development of a Promising Method for Producing Oligomeric Mixture of Branched Alkylene Guanidines to Improve Substance Quality and Evaluate Their Antiviral Activity against SARS-CoV-2
2021 · Denis O. Shatalov, Stanislav A. Kedik, et al. · Molecules · 5
PDF
Gut microbiome signature of Viliuisk encephalomyelitis in Yakuts includes an increase in microbes linked to lean body mass and eating behaviour
2020 · Veronika Kuznetsova, Alexander Tyakht, et al. · Orphanet Journal of Rare Diseases · 5
PDF
Inapparent Tick-Borne Orthoflavivirus Infection in Macaca fascicularis: A Model for Antiviral Drug and Vaccine Research
2023 · Victoria Illarionova, Anastasia Rogova, et al. · Vaccines · 4
PDF
CoviVac vaccination induces production of neutralizing antibodies against Delta and Omicron variants of SARS-CoV-2
2022 · Liubov Kozlovskaya, Ilya Gordeychuk, et al. · medRxiv · 4
PDF
Inactivated whole virion vaccine protects K18‐hACE2 Tg mice against the Omicron SARS‐CoV‐2 variant via cross‐reactive T cells and nonneutralizing antibody responses
2023 · Andrey A. Kruglov, Marina A. Bondareva, et al. · European Journal of Immunology · 3
PDF
Viral meningoencephalitis with damage to the right temporal lobe with a favorable outcome
2022 · T.V. Kirichenko, N.V. Turkot, et al. · S S Korsakov Journal of Neurology and Psychiatry · 1
Prospects for the Use of Combined Lysozyme Drugs in COVID-19
2021 · A.V. Gorelov, D.V. Usenko, et al. · Effective Pharmacotherapy · 1
PDF
Humoral and Cellular Immune Response to the Genetically Detoxified S1 Subunit of Pertussis Toxin in Mice
2025 · V. A. Shokina, A. V. Maleeva, et al. · Biochemistry (Moscow) Supplement Series A Membrane and Cell Biology
Author response for "Inactivated whole virion vaccine protects K18‐hACE2 Tg mice against Omicron SARS‐CoV‐2 variant via cross‐reactive T cells and non‐neutralizing antibody responses"
2023 · Andrey A. Kruglov, Marina A. Bondareva, et al. · Publons reviews and discussion
Author response for "Inactivated whole virion vaccine protects K18‐hACE2 Tg mice against Omicron SARS‐CoV‐2 variant via cross‐reactive T cells and non‐neutralizing antibody responses"
2023 · Andrey A. Kruglov, Marina A. Bondareva, et al. · Publons reviews and discussion
Determination of antibodies to SARS-CoV-2 in patients with coronavirus infection
2022 · G.M. Ignatyev, L.I. Kozlovskaya, et al. · Infectious diseases News Opinions Training
PDF
Additional file 2 of Gut microbiome signature of Viliuisk encephalomyelitis in Yakuts includes an increase in microbes linked to lean body mass and eating behaviour
2020 · Kuznetsova, Veronika, Tyakht, Alexander, et al. · Figshare
Works count: 29
Citation count: 294
H-index: 9
I10-index: 9
Year
Topic
Type